Clinical trials: Zoledronic acid
Hematopoietic Stem Cell Transplant, Bone Marrow Transplant
Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients
Patients who undergo bone marrow transplant for different types of cancer are exposed to many treatments such as steroids and whole body radiation.
- Trial name
- NCT02451462
- Testing
- Zoledronic acid
- Sponsor
- Stanford University
Renal Cell Cancer, Neoplasm Metastasis
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
It is the aim of this clinical study to evaluate the skeletal-related event rate under therapy with zoledronic acid in patients with renal cell cancer having at least one cancer-related bone lesion.
- Trial name
- NCT00172003
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Hip Fracture
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new)…
- Trial name
- NCT00046254
- Testing
- Zoledronic Acid
- Where
- 28 sites in United States, Germany
- Volunteers
- 2,127 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Maintaining Bone Strength in Men With Prostate Cancer
The purpose of this study is to see if giving zoledronic acid three times a year is as effective as five times a year, in increasing bone strength in men with prostate cancer.
- Trial name
- NCT00391950
- Testing
- Zoledronic acid
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Novartis
Osteoporosis
Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study
The aim of this study is to acquire preliminary, pilot data over a 2-year period on the safety and efficacy of subcutaneous denosumab versus the current CHEO standard-of-care (intravenous zoledronic acid) for the treatment of…
- Trial name
- NCT02632916
- Testing
- Zoledronic Acid, Denosumab
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Eastern Ontario
Seropositive Muskuloskeletal Complaints
Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints
Seropositive Rheumatoid arthritis (RA) is characterized by autoantibodies that develop prior to clinical onset, allowing identification of individuals at risk for disease development.
- Trial name
- PREVENT RA (NCT04115397)
- Testing
- Zoledronic Acid
- Volunteers
- 80 people
- Sponsor
- Karolinska Institutet
Cystic Fibrosis
Zoledronic Acid in Cystic Fibrosis
Null hypotheses: zoledronic acid does not improve bone density in cystic fibrosis. Low bone mineral density (osteoporosis) is prevalent in adults with cystic fibrosis (CF); they have an increased rate of bone fractures in…
- Trial name
- IZAC (NCT01702415)
- Testing
- Zoledronic acid
- Where
- United Kingdom
- Sponsor
- Papworth Hospital NHS Foundation Trust
Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer.
- Conditions
- Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer
- Trial name
- NCT01194440
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Heart Transplantation, Liver Transplantation
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
The purpose of this study is to compare the effectiveness and safety of zoledronic acid with alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is given as a single intravenous infusion.
- Conditions
- Heart Transplantation, Liver Transplantation, Bone Resorption
- Trial name
- CTX (NCT00297830)
- Testing
- Zoledronic acid, Alendronate
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Columbia University
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT02508038
- Testing
- TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer Metastatic
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
Exploring the efficacy and safety of zoledronic acid combined with neoadjuvant chemotherapy (EC-T) in neoadjuvant treatment for early-stage or locally advanced triple-negative breast cancer, the trial protocol of zoledronic acid…
- Trial name
- NCT06876636
- Testing
- Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Xijing Hospital
Myeloma
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
The purpose of this study test the hypothesis that the combination of simvastatin and zoledronic acid (for reversal of drug resistance), with bortezomib, high-dose methylprednisolone and bendamustine on a day 1,8 schedule (to…
- Trial name
- NCT01332617
- Testing
- Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
- Sponsor
- University of Louisville
Orthodontic Appliance Complication
Effect of Local Subperiosteal Zoledronic Acid Injection on the Survival of Orthodontic Miniscrews
Background: Orthodontic miniscrews are widely used as temporary anchorage devices; however, failure remains a clinical concern. Bisphosphonates may enhance bone stability, but evidence on their local application is limited.
- Trial name
- NCT07546058
- Testing
- Zoledronic Acid, Normal saline (0.9% sodium chloride)
- Where
- Syria
- Volunteers
- 68 people
- Sponsor
- Latakia University
Treatment of Bone Metastases
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
Zoledronic acid is a medication that slows the breakdown of bone. This study will assess the efficacy and safety of zoledronic acid in Chinese patients with multiple myeloma or other solid tumors with bone metastases.
- Trial name
- NCT00219258
- Testing
- Zoledronic acid
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Novartis
Breast Cancer, Osteoporosis
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
RATIONALE: It is not yet known whether zoledronate is effective in preventing bone loss in premenopausal women who are receiving adjuvant chemotherapy after undergoing surgery for early stage breast cancer.
- Trial name
- NCT00049452
- Testing
- zoledronic acid
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Early-stage Breast Cancer
Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
REaCT ZOL will compare one 4 mg dose of Zoledronate vs. one 4 mg dose of Zoledronate given every 6 months for 3 years.
- Trial name
- REaCT-ZOL (NCT03664687)
- Testing
- Zoledronate
- Where
- 6 sites in Canada
- Volunteers
- 211 people
- Sponsor
- Ottawa Hospital Research Institute
Giant Cell Tumors of Bone
Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zométa
The giant cell tumor (GTC) is an aggressive benign bone tumor, growing at the metaphyseal-epiphyseal regions of long bones, especially around the knee and the distal radius.It is responsible for bony destruction in para-articular…
- Trial name
- Zometa (NCT01564121)
- Testing
- acid Zoledronic
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
The purpose of this study is to examine the effect of simvastatin and zoledronic acid on M-protein and/or free light chains when added to conventional chemotherapy for the treatment of multiple myeloma patients.
- Trial name
- NCT01772719
- Testing
- Simvastatin and zoledronic acid
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Louisville
Postmenopausal Osteoporosis
Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
In contrast with bisphosphonates,discontinuation of denosumab results in gradual loss of bone mineral density gains. The investigators aim to evaluate whether in patients treated with denosumab, a single zoledronic acid infusion…
- Trial name
- AfterDmab (NCT02499237)
- Testing
- Denosumab, Zoledronic acid
- Where
- 2 sites in Greece
- Volunteers
- 57 people
- Sponsor
- 424 General Military Hospital
Secondary Osteoporosis
Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men
Clinical trial to assess the effectiveness of the supplement Colaren® associated with zoledronic acid 4mg/annually in the treatment of osteoporosis secondary, compared to standard treatment plus zoledronic acid 4mg/annually.
- Trial name
- OSZCO (NCT03930992)
- Testing
- Colaren in HIV positive, standard treatment in HIV positive, Colaren in HIV negative
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- University of Guadalajara